Pharmaceutical EthicsSam Salek, Andrew Edgar Wiley, 11. okt. 2002 - 216 sider Pharmaceutical Ethics is an important text, which aims to provide the ethical guidelines much needed by the pharmaceutical industry. By focusing on many of the central issues such as the ethical aspects of clinical trials, informed consent, physician or patient choice and pharmaceutical advertising, this text will provide very good coverage of an area which perhaps still lacks coherent instruction. * Covers ethical issues involved in the testing and use of pharmaceuticals on human beings * Investigates issues such as whether choice of drug should lie with the physician or the patient * Looks at a wide variety of subjects connected with pharmaceutical ethics. * Focuses specifically on the issues surrounding the pharmaceutical industry, not medicine in general. * Fulfils an important need in the Pharmaceutical Industry. |
Fra bogen
Resultater 1-3 af 14
Side 81
... a shorter regimen - less expensive - to placebo . The question raised by several authors is : should an effective treatment for which new studies versus placebo would be unethical Clinical Trials of Pharmaceuticals 81.
... a shorter regimen - less expensive - to placebo . The question raised by several authors is : should an effective treatment for which new studies versus placebo would be unethical Clinical Trials of Pharmaceuticals 81.
Side 82
... authors explained their hypotheses in the statistical methods section : " Based on an expected efficacy of 85 % with octreotide and 90 % with sclerotherapy , and a two - tailed test , alpha error 5 % , beta error 20 % , we estimated at ...
... authors explained their hypotheses in the statistical methods section : " Based on an expected efficacy of 85 % with octreotide and 90 % with sclerotherapy , and a two - tailed test , alpha error 5 % , beta error 20 % , we estimated at ...
Side 114
... authors estimated the cost of managing DRPs in this patient population at US $ 7.6 billion annually . Furthermore , deaths attributable to DRPs were estimated to occur in 3 to 4 % of nursing facility patients . The most comprehensive ...
... authors estimated the cost of managing DRPs in this patient population at US $ 7.6 billion annually . Furthermore , deaths attributable to DRPs were estimated to occur in 3 to 4 % of nursing facility patients . The most comprehensive ...
Indhold
The Basis of Ethics | 1 |
Principles of Ethics Focusing on the Patient | 13 |
Ethical Rationalism Applied to Pharmaceuticals | 27 |
Copyright | |
8 andre sektioner vises ikke
Andre udgaver - Se alle
Almindelige termer og sætninger
2002 John Wiley acceptable active adverse drug reactions advertising of medicines analysis antidepressant approach assessment autonomy behaviour benefit biomedical Bootman cancer choice clinical practice clinical trials cognitive condition cost culture debate decision decision-making Declaration of Helsinki depression and anxiety discourse ethics discussion disease doctor DRPs drug-related morbidity economic effective efficacy emotional ethics committee evaluation example factors gastro-oesophageal reflux disease guidelines H2 antagonists health professionals healthcare Hippocratic Oath hospital human individual informed consent involved medical ethics medical paternalism ment morbidity and mortality myocardial infarction NSAIDs Nuremberg Code participation person perspective Pharm Pharmaceutical Ethics pharmaceutical industry pharmacist pharmacoeconomic pharmacological pharmacy physician placebo potential prescribing prescription principles problems protocol Psychiatry psychotropic question rational reason requires responsibility result risk Salek scientific self-harmer social society strategies studies symptoms treat treatment unethical values